These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 36091837)

  • 21. Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review.
    Meijboom RW; Gardarsdottir H; Egberts TCG; Giezen TJ
    BioDrugs; 2022 Jan; 36(1):27-39. PubMed ID: 34870802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.
    Belleudi V; Trotta F; Addis A; Ingrasciotta Y; Ientile V; Tari M; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Trifirò G;
    Drug Saf; 2019 Dec; 42(12):1437-1447. PubMed ID: 31228010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel approach to support implementation of biosimilars within a UK tertiary hospital.
    Saxby K; Sanghvi S; Bodalia PN; Ferner RE; Leandro M; Urquhart R; Sofat R
    Br J Clin Pharmacol; 2020 Jan; 86(1):23-28. PubMed ID: 31663154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biosimilars in Dermatology - theory becomes reality.
    Gerdes S; Mrowietz U; Augustin M; Ralph von Kiedrowski ; Enk A; Strömer K; Schön MP; Radtke MA
    J Dtsch Dermatol Ges; 2018 Feb; 16(2):150-160. PubMed ID: 29364594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
    Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
    RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switching from Infliximab to Biosimilar in Inflammatory Bowel Disease: A Review of Existing Literature and Best Practices.
    Bhat S; Qazi T
    Crohns Colitis 360; 2021 Jan; 3(1):otaa093. PubMed ID: 36777069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Uptake of rheumatology biosimilars in the absence of forced switching.
    Di Giuseppe D; Frisell T; Ernestam S; Forsblad-D'Elia H; Lindqvist E; Lindström U; Sjöwall C; Askling J;
    Expert Opin Biol Ther; 2018 May; 18(5):499-504. PubMed ID: 29633865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
    Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F
    J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. European Stakeholder Learnings Regarding Biosimilars: Part II-Improving Biosimilar Use in Clinical Practice.
    Barbier L; Simoens S; Vulto AG; Huys I
    BioDrugs; 2020 Dec; 34(6):797-808. PubMed ID: 33063267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System.
    Bhardwaja B; Klocke S; Ekinci E; Jackson A; Kono S; Olson KL
    BioDrugs; 2022 Jan; 36(1):1-11. PubMed ID: 34817847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.
    McKinnon RA; Cook M; Liauw W; Marabani M; Marschner IC; Packer NH; Prins JB
    BioDrugs; 2018 Feb; 32(1):27-52. PubMed ID: 29344876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis.
    Ruda RC; Kelly KA; Feldman SR
    J Dermatolog Treat; 2023 Dec; 34(1):2140569. PubMed ID: 36305624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Costs associated with non-medical switching from originator to biosimilar etanercept in patients with rheumatoid arthritis in the UK.
    Tarallo M; Onishchenko K; Alexopoulos ST
    J Med Econ; 2019 Nov; 22(11):1162-1170. PubMed ID: 31373527
    [No Abstract]   [Full Text] [Related]  

  • 34. Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost-effectiveness?
    Roccuzzo G; Rozzo G; Burzi L; Repetto F; Dapavo P; Ribero S; Quaglino P
    Dermatol Ther; 2022 Nov; 35(11):e15803. PubMed ID: 36062429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes.
    Cohen HP; Blauvelt A; Rifkin RM; Danese S; Gokhale SB; Woollett G
    Drugs; 2018 Mar; 78(4):463-478. PubMed ID: 29500555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review.
    García-Beloso N; Altabás-González I; Samartín-Ucha M; Gayoso-Rey M; De Castro-Parga ML; Salgado-Barreira Á; Cibeira-Badia A; Piñeiro-Corrales MG; González-Vilas D; Pego-Reigosa JM; Martínez-López de Castro N
    Br J Clin Pharmacol; 2022 Feb; 88(4):1529-1550. PubMed ID: 34622969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review.
    Hillhouse E; Mathurin K; Bibeau J; Parison D; Rahal Y; Lachaine J; Beauchemin C
    Adv Ther; 2022 Jan; 39(1):455-487. PubMed ID: 34780028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Effectiveness of Multiple Switching Between Originators and Biosimilars: Literature Review and Status Report on Interchangeability.
    Lasala R; Abrate P; Zovi A; Santoleri F
    Ther Innov Regul Sci; 2023 Mar; 57(2):352-364. PubMed ID: 36322326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies.
    Cohen HP; Hachaichi S; Bodenmueller W; Kvien TK; Danese S; Blauvelt A
    BioDrugs; 2022 Sep; 36(5):625-637. PubMed ID: 35881304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends.
    Car E; Vulto AG; Houdenhoven MV; Huys I; Simoens S
    Front Pharmacol; 2023; 14():1151764. PubMed ID: 37153785
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.